For research use only. Not for use in humans.

Ulocuplumab (Anti-CXCR4 / CD184)

Synonyms: CXC-R4, CD184

Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Ulocuplumab (Anti-CXCR4 / CD184)

Quality Control

Batch: A252301 Purity: 99% Protein concentration: 6.72mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation CXCR1 CXCR2 CXCR4 CXCR3 Others
WZ811 21
Mavorixafor 0
AMG 487 4
Motixafortide (BL-8040, BKT140) 1 cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123) 9
MSX-122 1
LY2510924 2
Reparixin (Repertaxin) 26 CXCL8
SB 225002 91
Ladarixin 0
SB 265610 4
Balixafortide (POL6326) 1
SX-682 4
TAK-779 0 CCR5
MSX-130 0
MSX-127 0
AZD5069 6
Danirixin (GSK1325756) 2 CXCL8
LIT-927 8 CXCL12
AMD3465 hexahydrobromide 1
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD.

Product Details

CAS No. 1375830-34-4
Molecular Weight 144.84 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03225716 TERMINATED Drug: Ulocuplumab|Drug: Ibrutinib Waldenstrom's Macroglobulinemia Dana-Farber Cancer Institute 2017-10-20 PHASE1
NCT02305563 TERMINATED Drug: BMS-936564|Drug: Cytarabine Leukemia Bristol-Myers Squibb 2015-01-27 PHASE1; PHASE2
NCT02472977 TERMINATED Drug: Ulocuplumab|Drug: Nivolumab Solid Tumor Bristol-Myers Squibb 2015-07-13 PHASE1; PHASE2
NCT02115672 WITHDRAWN Drug: BL-8040 Chronic Myeloid Leukemia Sheba Medical Center 2014-11 PHASE1; PHASE2
NCT01359657 COMPLETED Multiple Myeloma Bristol-Myers Squibb 2011-09 PHASE1
NCT01120457 COMPLETED Drug: BMS-936564 (Anti-CXCR4) Acute Myelogenous Leukemia; Diffuse Large B-Cell Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma Bristol-Myers Squibb 2010-08 PHASE1

(data from https://clinicaltrials.gov, updated on 2024-05-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.